DJIA 16,102.38 -272.38 -1.66%
NASDAQ 4,683.92 -49.58 -1.05%
S&P 500 1,921.22 -29.91 -1.53%
market minute promo

ImmunoGen (NASDAQ: IMGN)

13.28 0.36 (2.79%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

IMGN $13.28 2.79%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $12.73
Previous Close $12.92
Daily Range $12.70 - $13.67
52-Week Range $5.34 - $19.43
Market Cap $1.2B
P/E Ratio -18.20
Dividend (Yield) $0.00 (0.0%)
Volume 938,647
Average Daily Volume 1,203,259
Current FY EPS -$1.42




Drug Makers

ImmunoGen (IMGN) Description

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website:

News & Commentary

Why Shares of ImmunoGen Inc Were Up Big Today

Shares of the cancer focused small-cap were up today on an otherwise down day for the markets.

Perilous Reversal Watch: Immunogen (IMGN)

ImmunoGen Inc: Finally Targeting Strong Returns?

This long-time sleepy stock has woken up recently on a flurry of good news. Does the future finally look bright for investors?

Why Cantor's Mara Goldstein Just Downgraded ImmunoGen

Benzinga's Top Downgrades

Analysts' Actions -- Bunge, Coach, Realogy and More

ImmunoGen: Back to a Development-Stage Biotech

With the biotech no longer collecting Kadcyla royalties, the pipeline becomes the focus of the release of quarterly earnings.

ImmunoGen's (IMGN) CEO Dan Junius on Q4 2015 Results - Earnings Call Transcript

ImmunoGen (IMGN) Q2 2015 Results - Earnings Call Webcast

ImmunoGen Is Climbing Higher... Again

ImmunoGen's shares continue to gain ground in the wake of early-stage trial results for its ovarian cancer drug.

See More IMGN News...

IMGN's Top Competitors

IMGN $13.28 (2.79%)
Current stock: IMGN
AMGN $147.02 (-1.48%)
Current stock: AMGN
GILD $102.06 (0.15%)
Current stock: GILD
BIIB $302.26 (0.21%)
Current stock: BIIB